<DOC>
	<DOCNO>NCT03044964</DOCNO>
	<brief_summary>The post-marketing study design evaluate activity level exercise tolerance patient defer percutaneous intervention due FFR ( fractional flow reserve ) great equal 0.81 treatment Ranolazine versus placebo .</brief_summary>
	<brief_title>Effect Ranolazine Activity Level Patients With Angina After FFR Based Deferred Intervention ( REPTAR )</brief_title>
	<detailed_description>Ranolazine approve Ranexa United States January 31 , 2006 treatment chronic angina . This post-marketing study single-center , double-blind , prospective , randomize , parallel-group evaluation patient randomize 1:1 Ranolazine placebo .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>1 . Subjects must willing able comply schedule visit , treatment plan , study procedure . 2 . There must evidence personally sign date informed consent document . 3 . Subjects must document history anginal chest pain equal great one ( 1 ) episode per week prior cardiac catheterization . 4 . Subjects must great equal one ( 1 ) episode angina chest pain screen visit randomization visit . 5 . Subject must document cardiac catheterization defer percutaneous intervention fractional flow reserve ( FFR ) great equal 0.81 within thirty ( 30 ) day , ( FFR ) less 0.81if candidate revascularization base upon operator discretion . 1 . Subjects congenital acquire QT interval prolongation ( great equal 440ms men/greater equal 460ms woman ) . 2 . Subjects prescibed strong CYP3A inhibitor ( include ketaconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir saquinavir . ) and/or strong CYP3A inducer ( rifampin , rifabutin , rifapentin , Phenobarbital , phenytoin , carbamezepine St. John 's wort ) . 3 . Subjects prescribe Simvastatin ( Zocor ) dose reduce appropriate level ( 20mg QD ) per physician medication discontinue clinical trial . 4 . Subjects prescribe Metformin dose reduce appropriate level ( less equal 850mg BID ) per physician medication discontinue clinical trial . 5 . Subjects prescribe Digoxin dose reduce appropriate level ( 0.125mg QD ) per physician medication discontinue clinical trial . 6 . Subjects life expectancy less duration trial . 7 . Subjects history liver cirrhosis . 8 . Subject chronic renal disease creatinine clearance less 30mL/min . 9 . Subjects participate clinical trial duration trial . 10 . Females childbearing potential , unwilling unable use highly effective method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Angina , Chest Pain</keyword>
</DOC>